A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy And Safety of Oral Azacitadine Plus Best Supportive Care Versus Best Supportive Care As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission.
The purpose of this stud is to determine if oral azacitadine is safe and effective as “maintenance therapy” in continuing the response patients had with their last AML treatment and improving the quality of that response.
Primary Sponsor: Celgene Corporation
Prinicipal Investigator: Imad Tabbara, M.D./Medicine; Division of Hematology/Oncology
Contact Phone: 202-741-2981
Are you interested in more information on this clinical trial?